MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Sangamo Therapeutics Total Liabilities 2011-2026 | SGMO
Annual Total Liabilities Sangamo Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.4 M | 268 M | 347 M | 441 M | 205 M | 223 M | 98.8 M | 21.7 M | 24.8 M | 36.6 M | 19.1 M | 17.6 M | 7.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 441 M | 7.2 M | 138 M |
Quarterly Total Liabilities Sangamo Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.4 M | 78 M | 72.1 M | 69.3 M | 84.8 M | 91.4 M | 105 M | 268 M | 285 M | - | 320 M | 347 M | 366 M | 390 M | 408 M | 441 M | 441 M | 441 M | 441 M | 205 M | 205 M | 205 M | 205 M | 223 M | 223 M | 223 M | 223 M | 98.8 M | 98.8 M | 98.8 M | 98.8 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 441 M | 7.2 M | 136 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
AC Immune SA
ACIU
|
119 M | $ 2.72 | 7.51 % | $ 229 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.81 | 1.28 % | $ 4.42 M |  China |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
argenx SE
ARGX
|
704 M | $ 840.28 | 1.7 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
1.47 B | $ 234.99 | 0.02 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.33 | 0.79 % | $ 8.01 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
25.8 M | $ 4.65 | 1.31 % | $ 392 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
2.55 M | $ 1.25 | - | $ 1.85 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.33 B | $ 62.62 | -0.48 % | $ 11.9 B | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 27.91 | 0.14 % | $ 747 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | $ 0.8 | 5.68 % | $ 109 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 12.65 | 10.29 % | $ 833 M | USA |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 169.95 | -2.75 % | $ 8.45 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
2.59 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
11.2 B | $ 195.13 | -0.62 % | $ 28.6 B | USA |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.98 | 0.51 % | $ 116 M | France |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Cellectar Biosciences
CLRB
|
25.9 M | $ 3.36 | 3.07 % | $ 41.1 M | USA |